Home  » Companies  » Biocon Ltd.

Biocon Ltd.

Price on BSE   16 Oct,15:29 LIVE
350.00
-1.50
(-0.43%)

© 2026 Rediff.com
  • Volume :
  • 668,342.00
  • Prev Close :
  • 351.50
  • Day's H/L (Rs.) :
  • 352.95 - 348.10
  • 52wk H/L (Rs.) :
  • 447.00 - 337.95
  • Mkt Cap (Rs. Cr) :
  • 57,039.50
Price on NSE   16 Oct,15:31 LIVE
349.20
-2.80
(-0.80%)

© 2026 Rediff.com
  • Volume :
  • 1,874,619.00
  • Prev Close :
  • 352.00
  • Day's H/L (Rs.) :
  • 353.00 - 348.00
  • 52wk H/L (Rs.) :
  • 447.15 - 337.70
  • Mkt Cap (Rs. Cr) :
  • 0.00

View more

Market News

HSBC emerges as top international bank for Indian corporate fundraising
Rediff.com   5 day(s) ago
Lupin eyes $500 million from biosimilars, expands global footprint
Rediff.com   15 Sep 2026
Indian drugmakers in no rush to shift to US despite tariff threat
Rediff.com   10 Aug 2026
Report Card - Biocon Ltd.
PE Ratios
1,525.13
EPS (Rs.)
0.23
Sales (Rs. Cr)
624.50
Face Value (Rs.)
5
Net Profit Margin(%)
1.58
Last Bonus
1:1
Last Dividend(%)
10
Return on Average Equity
0.13

News for Biocon Ltd.

Biocon Settles Patent Dispute for Breast Cancer Drug Pebrilzo
Biocon reaches global patent settlement with Genentech for its breast cancer biosimilar, Pebrilzo. Launches planned for EU/UK (2027) and US (2028).
Oct 14, 2026 13:13
Biocon Receives Rs 3.2 Cr GST Demand Notice for FY23
Biotechnology firm Biocon has been issued a GST demand notice of over Rs 3.2 crore, including interest and penalty, for the 2022-23 financial year. The company plans to appeal.
Oct 10, 2026 20:16
Indian Pharma Shifts to Innovation-Led Growth: Leaders Say
Industry leaders foresee India's pharma sector transitioning from generics to innovation, driven by R&D, talent, and supportive policies. A critical decade ahead.
Oct 05, 2026 13:42
Biocon Malaysia Gets UK MHRA Approval for Insulin Unit
Biocon Malaysia secures UK MHRA approval for its new fill-finish unit for Semglee (insulin glargine). This follows earlier EMA approval for the facility.
Sep 25, 2026 13:27
Biocon's Pebrilzo Gets Positive EMA Panel Nod for Breast Cancer
Biocon Biologics' Pebrilzo, a Pertuzumab biosimilar for HER2-positive breast cancer, receives positive EMA panel recommendation, moving closer to EU approval.
Sep 21, 2026 12:10

More News for Biocon Ltd. »

About Biocon Ltd.

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Wikipedia

News for Pharmaceuticals

HDFC Bank Q2 Net Profit Rises 5.55% to Rs 20,700 Cr
HDFC Bank reports 5.55% rise in Q2 consolidated net profit to Rs 20,700 crore. Standalone profit grew 4.7%, total income increased, and NPA ratio improved.
Oct 17, 2026 15:21
DLF's Growth Engines: Housing Sales, Margins, Rental Income
DLF focuses on strong luxury home pre-sales, healthy profit margins, and growing rental income from commercial properties, reporting robust Q2 results.
Oct 17, 2026 14:40
Axis Bank Q2 Net Profit Jumps 39% to Rs 7,704 Cr
Axis Bank reports a 39% surge in Q2 net profit to Rs 7,704 crore, driven by strong NII growth, robust advances, and improved asset quality.
Oct 17, 2026 14:17
India's Russian Crude Imports Continue After Trump Waiver
Trump waives sanctions on Russian oil buyers, ensuring India can maintain its high crude imports. This prevents global price spikes and benefits Indian refiners.
Oct 17, 2026 14:00
Renault India: Hybrids & CNG to Drive 50% Sales Growth
Renault India CEO predicts hybrids and CNG will account for 50% of sales in 2-3 years, launching Duster Strong Hybrid and expanding multi-fuel strategy.
Oct 17, 2026 13:05

More News »

Top News

HDFC Bank Q2 Net Profit Rises 5.55% to Rs 20,700 Cr
HDFC Bank reports 5.55% rise in Q2 consolidated net profit to Rs 20,700 crore. Standalone profit grew 4.7%, total income increased, and NPA ratio improved.
Oct 17, 2026 15:21
DLF's Growth Engines: Housing Sales, Margins, Rental Income
DLF focuses on strong luxury home pre-sales, healthy profit margins, and growing rental income from commercial properties, reporting robust Q2 results.
Oct 17, 2026 14:40
New Steel Policy: Circular Economy, Value Addition, Decarbonization
India's new steel policy aims to boost circular economy, value-added production, and decarbonization. Industry leaders welcome focus on capacity, raw materials, and MSMEs.
Oct 17, 2026 14:20
Axis Bank Q2 Net Profit Jumps 39% to Rs 7,704 Cr
Axis Bank reports a 39% surge in Q2 net profit to Rs 7,704 crore, driven by strong NII growth, robust advances, and improved asset quality.
Oct 17, 2026 14:17
India's Russian Crude Imports Continue After Trump Waiver
Trump waives sanctions on Russian oil buyers, ensuring India can maintain its high crude imports. This prevents global price spikes and benefits Indian refiners.
Oct 17, 2026 14:00

More Top News »

Our Services

News Movies Sports Cricket Business Get Ahead Gurus Astrology Rediff-Tv Business Email Rediff Podcast Payments